To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Cystic Fibrosis Patients Showed Significant Improvement With HP-3 URL: http://www.pslgroup.com/dg/15007E.htm Doctor's Guide December 13, 1999
BOXFORD, MA. -- December 13, 1999 -- Milkhaus Laboratory, Inc. announced that a Phase II clinical trial of its product, HP-3, was successful in treating patients with cystic fibrosis. The results showed significant improvement in pulmonary function and an increase in sputum clearance. Cystic fibrosis is a chronic, inherited disease of the exocrine glands that affects children and young adults. Thick mucus builds up in the lungs which severely limits pulmonary function and the ability to carry out normal activities of living. Chronic lung infections are common and damage to lung tissue occurs as a result of inflammation and chronic oxygen deprivation. There is no effective treatment for the disease. Products currently available offer only nominal improvements in symptoms for the 35,000 patients in the U.S. Commenting on this trial, the Company's CEO, Dr. John McMichael, said: "Our cystic fibrosis trial was one of three we conducted using HP-3 in patients with diseases involving respiratory distress caused by sputum or scar tissue blocking the airways. The other trials were in chronic bronchitis and chronic obstructive pulmonary disease, or COPD. In all three, HP-3 increased sputum expectoration and significantly improved pulmonary function. We believe it evokes such responses through a mechanism common to all three disease categories. As a result, the product has very broad potential utility in relieving the debilitating symptoms of respiratory distress which afflict more than 15 million people in the U.S. Furthermore, results suggest that it does so safely and without the need to limit the use of other medications." --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.